B-Raf IN 2
CAS No. 2649372-20-1
B-Raf IN 2( —— )
Catalog No. M35194 CAS No. 2649372-20-1
B-Raf IN 2, compound Ia, is a highly effective and specific inhibitor of BRAF. It exhibits significant potential for cancer research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 79 | Get Quote |
|
| 5MG | 121 | Get Quote |
|
| 10MG | 188 | Get Quote |
|
| 25MG | 325 | Get Quote |
|
| 50MG | 455 | Get Quote |
|
| 100MG | 626 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameB-Raf IN 2
-
NoteResearch use only, not for human use.
-
Brief DescriptionB-Raf IN 2, compound Ia, is a highly effective and specific inhibitor of BRAF. It exhibits significant potential for cancer research.
-
DescriptionB-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancer.
-
In VitroB-Raf IN 2 shows considerably less paradoxial activation of the MAPK signaling pathway while retaining high potency.
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetRaf
-
RecptorRaf
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2649372-20-1
-
Formula Weight461.44
-
Molecular FormulaC20H17F2N5O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (216.71 mM; Ultrasonic )
-
SMILESCn1cnc2ccc(Oc3c(F)ccc(NS(=O)(=O)N4CC[C@@H](F)C4)c3C#N)cc2c1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Dolente C, et, al. New methylquinazolinone derivatives. WO2021116055A1.
molnova catalog
related products
-
Dabrafenib Mesylate
Dabrafenib Mesylate is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively).
-
LXH254
LXH254 (LXH-254, LXH 254) is a novel potent, ATP-competitive pan-RAF inhibitor, binds to Raf proteins and inhibits Raf-mediated signal transduction pathways.
-
LUT014
LUT014 is a B-Raf inhibitor (IC50: 11.7 nM) and developed to decrease dose-limiting acneiform lesions associated with EGFR Inhibitors treatment.
Cart
sales@molnova.com